Amplyx touts upbeat readout from a small PhII study for lead antifungal
Amplyx, a biotech focused on treating patients with compromised immune systems, is touting its lead program following a Phase II study.
The San Diego-based company announced its results Monday morning for fosmanogepix, an antifungal that treats life-threatening Candida infections. Execs at the company say that topline data from the study indicated a treatment success rate of 80 percent, meeting the primary endpoint and paving the way to a pivotal trial ahead.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.